Meyka Pro banner
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK) Stock Competitors & Peer Comparison

See (3378.HK) competitors and their performances in Stock Market.

3378.HKHKSE
HealthcareBiotechnology
HK$25.84
HK$1.72(6.24%)
Hong Kong Market is Open · 15:51

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
3378.HKHK$26.80-5.17%3.7B117.36HK$0.23N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$196.50+2.61%260.3B87.25HK$2.21N/A
2269.HKHK$38.84+1.52%160.9B30.38HK$1.28N/A
1801.HKHK$92.25-0.27%160.4B169.46HK$0.54N/A
6990.HKHK$517.00+2.58%119.3B-253.59-HK$2.02N/A
9926.HKHK$98.90+5.95%87B-70.52-HK$1.34N/A
3347.HKHK$38.16-0.10%45.6B38.42HK$0.98+0.39%
6821.HKHK$118.90-1.74%44.2B40.13HK$3.05+1.22%
1530.HKHK$17.29+2.13%42.3B4.41HK$3.84+1.48%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

3378.HK vs 4332.HK Comparison July 2026

3378.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 3378.HK stands at 3.7B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 3378.HK is priced at HK$26.80, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

3378.HK currently has a P/E ratio of 117.36, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 3378.HK's ROE is +0.13%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 3378.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 3378.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions